Teva Loses Copaxone Patent Case, Boosting Momenta Stock
By Catherine Shaffer
Tuesday, July 30, 2013
In a patent infringement appeal filed by Momenta Pharmaceuticals Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals, the Court of Appeals for the Federal Circuit declared some patents for Teva Pharmaceutical Industries Ltd.'s multiple sclerosis (MS) drug, Copaxone (glatiramer acetate injection), to be invalid.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.